GLP-1 Medications: Side Effects tamed, benefits retained?

Small or fractional doses of GLP-1 receptor agonists may mitigate side effects while retaining some therapeutic benefits, though this approach requires further long-term research and is not considered a complete replacement for standard treatments. The Challenge of Tolerability A primary hurdle in using GLP-1 medications is poor tolerability. Patients frequently report nausea, vomiting, diarrhea, and constipation. To manage these adverse reactions, physicians typically employ a gradual dose escalation strategy. For instance, semaglutide begins at 0.25 mg weekly, liraglutide at 0.6 mg daily, and tirzepatide at 2.5 mg weekly. However, specialists are exploring the possibility that some patients might achieve significant clinical results with consistently lower doses. This concept suggests that maintaining a lower dose could offer a more manageable treatment regimen.